Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilitiesHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilitiesGlobeNewswireJanuary 7, 2020ReblogShareTweetShareOrphazyme A/SCompany announcement                                                                                       No. 04/2020                                                                                                        Company Registration No. 32266355Copenhagen, Denmark, January 7, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme:1 Details of the Reporting Person / Closely Associated Persona) NameKim Stratton2 Reason for the notification a) Position/statusChief Executive Officerb) Initial notification/AmendmentInitial notification3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor a) NameOrphazyme A/Sb) LEI code54930025OZD2GGSQ7L424 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument and identification codeSharesISIN DK0060910917b) Nature of the transactionPurchase of sharesc) Price(s) and volume(s) Price (s) Volume(s)
DKK   76.40   10
DKK   76.40   100
DKK   76.40   1,318
DKK   76.60   575
DKK   76.80   490
DKK   76.80   1,500
DKK   76.80   564
DKK   76.80   50
DKK   77.00   143
DKK   77.00   1,000
DKK   76.80   91
DKK   77.00   1,000
DKK   77.00   1,000
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   407
DKK   77.00   186
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   407
DKK   77.00   186
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   407
DKK   77.00   593
DKK   77.00   1,000
DKK   77.00   253
DKK   77.00   873
DKK   77.00   627
DKK   77.00   23
DKK   77.00   362
DKK   77.00   170
DKK   77.00   180
DKK   77.00   150
DKK   77.00   13
DKK   77.00   1,987
DKK   77.00   405
DKK   77.00   529
DKK   77.00   406
DKK   77.00   85
DKK   77.00   575
DKK   77.00   21 d) Aggregated informationAggregated volumePriceAggregated volume: 31,500Price: DKK 76.948387 (volume weighted average)e) Date of the transaction2020-01-03 between 12:15 and 12:29 UTCf) Place of the transactionNasdaq Copenhagen A/S - XCSEFor additional information, please contactOrphazyme Anders Vadsholt, CFO                                                        +45 28 98 90 55About Orphazyme A/S Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com. Forward-looking statement This company announcement may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.  Story continuesAttachment 04-2020 Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceQ4 e-commerce sales are what's 'saving Walmart': AnalystYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo FinanceWhat to watch in the markets: Friday, February 28Yahoo Finance VideoHackers Breach Ring Home Security CamerasYahoo Finance Video